249 related articles for article (PubMed ID: 29425664)
1. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.
Grabner M; Bodhani A; Khandelwal N; Palli S; Bonine N; Khera M
J Sex Med; 2017 Jan; 14(1):88-97. PubMed ID: 27939338
[TBL] [Abstract][Full Text] [Related]
3. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
Chen T; Li S; Eisenberg ML
J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
[TBL] [Abstract][Full Text] [Related]
4. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
Schoenfeld MJ; Shortridge E; Cui Z; Muram D
J Sex Med; 2013 May; 10(5):1401-9. PubMed ID: 23464534
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
Rhoden EL; Morgentaler A
J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
[TBL] [Abstract][Full Text] [Related]
6. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
Khera M; Miner M; Jaffe J; Pastuszak AW
J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
[TBL] [Abstract][Full Text] [Related]
9. The direct and indirect costs among U.S. privately insured employees with hypogonadism.
Kaltenboeck A; Foster S; Ivanova J; Diener M; Bergman R; Birnbaum H; Kinchen K; Swindle R
J Sex Med; 2012 Sep; 9(9):2438-47. PubMed ID: 22738380
[TBL] [Abstract][Full Text] [Related]
10. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
[TBL] [Abstract][Full Text] [Related]
11. Association of Male Hypogonadism With Risk of Hospitalization for COVID-19.
Dhindsa S; Champion C; Deol E; Lui M; Campbell R; Newman J; Yeggalam A; Nadella S; Ahir V; Shrestha E; Kannampallil T; Diwan A
JAMA Netw Open; 2022 Sep; 5(9):e2229747. PubMed ID: 36053534
[TBL] [Abstract][Full Text] [Related]
12. Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.
Muram D; Kaltenboeck A; Boytsov N; Hayes-Larson E; Ivanova J; Birnbaum HG; Swindle R
Am J Mens Health; 2015 Nov; 9(6):496-505. PubMed ID: 25271142
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
[TBL] [Abstract][Full Text] [Related]
14. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
15. Glycemic benefits with adherence to testosterone therapy in men with hypogonadism and type 2 diabetes mellitus.
Jenkins CR; Rittel A; Sturdivant RX; Wan J; Clerc PG; Manning E; Jenkins LM; Wardian JL; Graybill SD
Andrology; 2021 Jul; 9(4):1076-1085. PubMed ID: 33606360
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
Saad F; Caliber M; Doros G; Haider KS; Haider A
Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
[No Abstract] [Full Text] [Related]
19. Associations of Renin-Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study.
Campbell PJ; Axon DR; Taylor AM; Pickering M; Black H; Warholak T; Chinthammit C
J Am Heart Assoc; 2020 Sep; 9(17):e016094. PubMed ID: 32844732
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment patterns of testosterone replacement medications.
Donatucci C; Cui Z; Fang Y; Muram D
J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
